Aspira Women's Health Reports Material Agreements & Officer Changes
Ticker: AWHL · Form: 8-K · Filed: Apr 8, 2025 · CIK: 926617
| Field | Detail |
|---|---|
| Company | Aspira Women'S Health INC. (AWHL) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, officer-changes
Related Tickers: AWH
TL;DR
Aspira Women's Health (AWH) filed an 8-K detailing new deals, stock sales, and exec changes on April 2nd.
AI Summary
Aspira Women's Health Inc. filed an 8-K on April 8, 2025, reporting on several key events that occurred on April 2, 2025. These include entering into a material definitive agreement, unregistered sales of equity securities, and changes related to director and officer positions, including compensatory arrangements. The filing also covers other events and financial statements.
Why It Matters
This 8-K filing indicates significant corporate actions, including potential new agreements and changes in leadership or compensation, which could impact the company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity securities, which can carry inherent risks related to deal terms, dilution, and regulatory compliance.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Filer of the 8-K report
- April 2, 2025 (date) — Date of earliest event reported
- April 8, 2025 (date) — Date of report filing
FAQ
What was the nature of the material definitive agreement entered into by Aspira Women's Health?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities, but the specific type and amount of securities are not detailed in the provided summary.
Were there any departures or elections of directors or officers on April 2, 2025?
Yes, the filing reports on the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as compensatory arrangements.
What is the SIC code for Aspira Women's Health Inc.?
The Standard Industrial Classification (SIC) code for Aspira Women's Health Inc. is 2835, which pertains to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
What were the former names of Aspira Women's Health Inc.?
Aspira Women's Health Inc. was formerly known as VERMILLION, INC. (name change effective August 24, 2007), CIPHERGEN BIOSYSTEMS INC (name change effective March 16, 2000), and ABIOTIC SYSTEMS (name change effective April 7, 1995).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 8, 2025 regarding Aspira Women's Health Inc. (AWHL).